181 related articles for article (PubMed ID: 16995580)
1. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
[TBL] [Abstract][Full Text] [Related]
2. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
[TBL] [Abstract][Full Text] [Related]
6. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
Bertelloni S; Mucaria C; Baroncelli GI; Peroni D
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
[TBL] [Abstract][Full Text] [Related]
7. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
[TBL] [Abstract][Full Text] [Related]
8. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
Liang Y; Wei H; Zhang JL; Hou L; Luo XP
Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
[TBL] [Abstract][Full Text] [Related]
10. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
[TBL] [Abstract][Full Text] [Related]
11. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
12. Central precocious puberty: treatment with triptorelin 11.25 mg.
Chiocca E; Dati E; Baroncelli GI; Cassio A; Wasniewska M; Galluzzi F; Einaudi S; Cappa M; Russo G; Bertelloni S
ScientificWorldJournal; 2012; 2012():583751. PubMed ID: 22645436
[TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation
.
Durand A; Tauber M; Patel B; Dutailly P
Horm Res Paediatr; 2017; 87(4):224-232. PubMed ID: 28334719
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.
Liang Y; Wei H; Zhang J; Hou L; Luo X
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):558-61. PubMed ID: 17219967
[TBL] [Abstract][Full Text] [Related]
15. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
16. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
[TBL] [Abstract][Full Text] [Related]
17. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.
Oostdijk W; Hümmelink R; Odink RJ; Partsch CJ; Drop SL; Lorenzen F; Sippell WG; van der Velde EA; Schultheiss H
Eur J Pediatr; 1990 Feb; 149(5):308-13. PubMed ID: 2138079
[TBL] [Abstract][Full Text] [Related]
18. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
[TBL] [Abstract][Full Text] [Related]
19. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.
Roth CL; Brendel L; Rückert C; Hartmann K
Horm Res; 2005; 63(5):257-62. PubMed ID: 15995342
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study.
Lasorella S; Porto R; Iezzi ML; Pistone C; Marseglia GL; Verrotti A; Brambilla I
Gynecol Endocrinol; 2020 Apr; 36(4):338-340. PubMed ID: 31441342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
